Amosulalol - Astellas Pharma/LTL Pharma

Drug Profile

Amosulalol - Astellas Pharma/LTL Pharma

Alternative Names: Lowgan; LY 137224; YM 09538

Latest Information Update: 07 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; LTL Pharma
  • Class Antihypertensives; Ethanolamines; Small molecules; Sulfonamides
  • Mechanism of Action Alpha beta adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 05 Jul 1999 No-Development-Reported for Hypertension in South Korea (PO)
  • 05 Jul 1999 No-Development-Reported for Hypertension in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top